PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
2.27
Current Ratio near Drug Manufacturers - Specialty & Generic median of 2.13. Charlie Munger would see it as typical for the industry.
1.42
Quick Ratio 0.75–0.9x Drug Manufacturers - Specialty & Generic median of 1.61. John Neff might push for better working capital control.
0.76
Cash Ratio 1.25–1.5x Drug Manufacturers - Specialty & Generic median of 0.57. Mohnish Pabrai might see the market undervaluing high immediate liquidity.
-0.92
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
0.92
Short-term coverage of 0.92 versus zero Drug Manufacturers - Specialty & Generic median. Walter Schloss would verify if our cash flow management provides advantages.